Blue, red, and near-infrared light each penetrate tissue to different depths and activate distinct biological pathways. Here is the science, the evidence, and how the devices we feature fit into the picture.
Light is energy, and the body knows what to do with it. Photobiomodulation (PBM) — also called low-level laser therapy (LLLT) or red light therapy — is the therapeutic use of specific wavelengths of light to trigger biological responses at the cellular level. Unlike heat-based treatments or UV exposure, PBM uses non-thermal light: your tissues absorb it without being heated or damaged. The result is a cascade of cellular signaling that supports energy production, reduces inflammation, and promotes tissue recovery.
This page covers the full photobiomodulation spectrum as it applies to the devices we feature at Resonance Health Hub — including blue light (400–500nm), red light (600–700nm), and near-infrared (NIR) light (700–1100nm). Each wavelength has a distinct depth of penetration and a distinct biological target. The devices we work with — the Glowing IC Pad 3 (blue 450nm, red 630nm, NIR 850nm) and the Kineon MOVE+ Pro (red 660nm LEDs + 808nm Class 1 lasers) — use different parts of this spectrum for different purposes.
The Three Wavelength Bands: What Each One Does
The core principle of photobiomodulation is simple: different wavelengths of light penetrate tissue to different depths and activate different biological pathways. Shorter wavelengths (blue) stay near the surface. Longer wavelengths (NIR) reach deep into joints, muscle, and bone. Red sits in between — penetrating 2–5mm into tissue and activating the most well-studied cellular mechanism in PBM research.
400–500nm
Particularly 415–450nmPhotoreceptors: Flavin-based photoreceptors (FAD), not cytochrome c oxidase. Produces targeted, low-level reactive oxygen species at the skin surface.
Best supported uses: Skin health, acne (antimicrobial), surface inflammation, circadian rhythm support.
600–700nm
Particularly 630–660nmPhotoreceptors: Cytochrome c oxidase (Complex IV). Stimulates ATP production, reduces oxidative stress, modulates nitric oxide signaling.
Best supported uses: Wound healing, surface pain, skin tissue repair, inflammation — strongest evidence base in the red spectrum.
700–1100nm
Particularly 808–850nm and 1064nmPhotoreceptors: Cytochrome c oxidase (same as red) plus deeper anti-inflammatory and neurological effects. Laser delivery enables precise focal energy at depth.
Best supported uses: Deep joint and muscle recovery, brain photobiomodulation, neurological support, athletic recovery.
How It Works: Cytochrome c Oxidase and the Mitochondria
The most well-established mechanism of photobiomodulation centers on cytochrome c oxidase — the terminal enzyme of the mitochondrial electron transport chain (Complex IV). In normal cellular function, cytochrome c oxidase drives ATP synthesis by facilitating electron transfer to oxygen. Under conditions of oxidative stress, nitric oxide (NO) competitively inhibits this enzyme, slowing ATP production and impairing cellular function.
Red and NIR light photons are absorbed directly by cytochrome c oxidase. This absorption dissociates the inhibitory nitric oxide, restores electron transport, and allows ATP synthesis to resume. The downstream effects are well-documented:
- Increased ATP production — more cellular energy available for repair and function
- Reduced reactive oxygen species (ROS) — lower oxidative stress burden
- Nitric oxide release — vasodilation and improved local circulation
- Anti-inflammatory signaling — reduced pro-inflammatory cytokine expression
- Upregulated gene expression — for growth factors, antioxidant enzymes, and repair proteins
Blue Light: Surface Action and Antimicrobial Effects
Blue light (400–500nm) operates through a different mechanism than red and NIR. Rather than acting primarily through cytochrome c oxidase, blue light is absorbed by flavin-based photoreceptors — including flavin adenine dinucleotide (FAD) — producing reactive oxygen species at very low, localized levels. This localized ROS activity has demonstrated antimicrobial effects against a range of pathogens including Cutibacterium acnes (the primary bacteria involved in acne) and produces anti-inflammatory effects at the skin level.5
Blue light penetrates less than 1mm below the skin surface. This makes it particularly effective for surface-level applications — acne treatment, wound surface antimicrobial support, and circadian rhythm modulation (morning blue light exposure signals wake-time to the suprachiasmatic nucleus). It is not a deep-penetrating therapy, and using it as a sole treatment for joint pain or systemic inflammation is not well-supported by evidence.
The Glowing IC Pad 3 includes blue (450nm), red (630nm), and NIR (850nm) LEDs alongside its primary IC imprinting function. The blue component adds real, documented surface-level PBM benefit. However, the Glowing IC Pad 3 is not a dedicated, high-power PBM device — its light output is calibrated for IC delivery and general wellness use. If targeted deep joint photobiomodulation is the primary goal, the Kineon MOVE+ Pro is the more appropriate tool.
Red Light: The Cytochrome c Oxidase Workhorse
Red light (600–700nm) is the most clinically studied wavelength range in photobiomodulation. Whereas blue light works through flavin-based photoreceptors at the skin surface, red light is absorbed directly by cytochrome c oxidase — the terminal enzyme of the mitochondrial electron transport chain. The 630–660nm window in particular sits within the absorption peaks of cytochrome c oxidase, which is why this is the wavelength range most studies use when investigating ATP production, oxidative stress reduction, and tissue repair.6,8
Red light penetrates 2–5mm below the skin surface — deep enough to reach the dermal layer where fibroblasts produce collagen, but not deep enough to reach joints, deep muscle, or bone. This depth profile is why red light dominates the evidence base for skin applications: wound healing, scar remodeling, collagen stimulation, and surface anti-inflammatory effects. A 2024 systematic review on photobiomodulation in osteoarthritis confirmed that benefit in superficial joints (like the hand and finger) is strongly tied to red wavelengths, while deeper joints require NIR delivery.9
Red light at 660nm is also where the largest body of consumer device research has been generated. Wunsch and Matuschka’s controlled trial demonstrated measurable improvements in skin elasticity and reduction in fine lines after 12 weeks of regular 660nm exposure, and subsequent studies have replicated this finding at fluences in the 8–15 J/cm² range.10 The biphasic dose-response (Arndt–Schulz law) applies particularly clearly here: under-dosing produces no effect, and over-dosing actually counteracts collagen stimulation through oxidative stress.
The Kineon MOVE+ Pro uses 660nm LEDs as its red-light component, paired with 808nm Class 1 lasers for deeper joint reach. The 660nm contributes the surface and superficial-tissue effects — collagen support, surface anti-inflammatory effects, and the cytochrome c oxidase activation profile most consistent with the published research. The Glowing IC Pad 3 uses 630nm rather than 660nm; both sit within the cytochrome c oxidase absorption window, though 660nm has been the more frequently studied wavelength in clinical trials.
Near-Infrared Light: Depth, Joints, and Brain Photobiomodulation
Near-infrared (NIR) light (700–1100nm) extends the cytochrome c oxidase mechanism into the body’s deeper tissues. The same photoreceptor mechanism applies — NIR photons are absorbed by Complex IV, dissociate inhibitory nitric oxide, and restore mitochondrial electron transport — but the wavelengths in the 808–850nm window penetrate 5–10cm into tissue, reaching joints, deep muscle, and even the brain. This is the wavelength range where most musculoskeletal pain, athletic recovery, and neurological pilot research has been conducted.2,4
The 808nm wavelength has the strongest clinical trial base of any NIR wavelength. It is the wavelength used in the largest number of low-level laser therapy trials, particularly for wound healing, neural regeneration, and joint pathology, and it appears in clinical-grade laser devices more often than any other NIR frequency.11 The 850nm wavelength penetrates marginally deeper but has a smaller research base. In practice, 808nm and 850nm are often considered functionally similar for tissue-level applications — the differences are real but modest, and device quality, power output, and treatment duration matter as much as the specific wavelength chosen within this window.
For brain photobiomodulation specifically, NIR is the only wavelength that reaches the cortex through the skull. Transcranial application (NIR shone directly through the scalp) and intranasal application (NIR delivered through the nasal cavity’s vascular bed toward the brain’s base) are the two delivery routes with active clinical research. Hamblin’s review catalogued early signals for cognitive support, traumatic brain injury recovery, and neurodegenerative conditions.4 See the Vielight device page for the specific intranasal-transcranial research context.
The Kineon MOVE+ Pro uses 808nm Class 1 lasers — the wavelength with the strongest clinical-trial base and the laser delivery format that enables focused, focal energy at joint depth. This is intentional: broad LED panels at 850nm cannot replicate the precision of laser delivery into the joint space. The Glowing IC Pad 3 uses 850nm LEDs for general wellness PBM. The Vielight devices use 810nm specifically for intranasal-transcranial brain application, where the wavelength’s known behavior through cranial tissue is particularly well-documented.
What the Research Shows: Evidence by Application Area
The research base for photobiomodulation is broad and growing. The strongest evidence is in wound healing and musculoskeletal pain. Neurological applications are an active area of investigation with meaningful pilot data. Here is an honest summary by application area.
Wound Healing and Tissue Repair
This is the strongest application area across the PBM literature. Multiple randomized controlled trials demonstrate accelerated wound closure, improved collagen synthesis, and reduced healing time. FDA-cleared devices exist for wound healing indications. The cytochrome c oxidase mechanism is particularly well-matched to this application — ATP production and reduced oxidative stress are directly relevant to the cellular demands of tissue repair.1
The device parameters that produce optimal outcomes (wavelength, power density, fluence, treatment frequency) vary across wound types. Extrapolating from wound healing studies to other applications requires care.
Musculoskeletal Pain and Inflammation
A growing body of RCTs supports PBM — particularly red and NIR light — for knee pain, neck pain, shoulder pain, and low back pain. A 2022 systematic review found significant short-term pain reduction and improved function in knee osteoarthritis with NIR PBM versus sham.2 Effect sizes are variable across studies, largely driven by differences in device parameters and treatment protocols.
The Kineon MOVE+ Pro targets this application directly. The 660nm LEDs address surface anti-inflammatory and tissue-level effects; the 808nm Class 1 lasers provide focused NIR delivery at joint depth — replicating the parameters of several positive clinical trials at the device level.
Effect sizes vary substantially between studies. Device parameters, treatment duration, and baseline severity all affect outcomes. Not all musculoskeletal pain presentations respond equally.
Skin Health — Acne and Surface Inflammation
Blue and red light are well-documented for acne treatment, with several RCTs and a Cochrane review supporting their use. Blue light (415nm) targets C. acnes directly via porphyrin photoactivation; red light adds anti-inflammatory depth. The combination is more effective than either wavelength alone in several comparative trials.5
For photoaging and skin rejuvenation, red light PBM has demonstrated collagen stimulation and wrinkle reduction in multiple controlled studies, with an acceptable safety profile.
Athletic Recovery
NIR and red light PBM applied before or after exercise has been studied for muscle fatigue reduction, delayed onset muscle soreness (DOMS), and performance conditioning. A 2016 meta-analysis of 13 RCTs found significant reductions in post-exercise muscle soreness and improved recovery markers with PBM versus sham.3 Pre-exercise application appears particularly promising for performance conditioning, with studies showing improved endurance and reduced fatigue.
Most positive trials used clinical-grade devices with calibrated power outputs. Consumer device studies are fewer, and dose-response relationships are still being established.
Brain and Cognitive Support (Transcranial and Intranasal PBM)
Transcranial and intranasal NIR photobiomodulation is an active research area with meaningful pilot data. The brain’s high metabolic demand and density of mitochondria make it a plausible target for cytochrome c oxidase activation. Intranasal delivery (as used by Vielight) routes NIR light through the nasal cavity’s rich vascular supply directly toward the brain’s base.
Hamblin’s 2016 review catalogued early signals for cognitive support, Alzheimer’s disease, and traumatic brain injury recovery.4 Vielight’s own trials have shown improvements in cognition and brain connectivity in small controlled studies. This is a genuinely promising area — but controlled, adequately powered trials are still limited. See the Vielight device page for the specific research context.
No PBM device has FDA clearance for neurological indications. Brain PBM is wellness support — not medical treatment for Alzheimer’s disease or any other neurological condition.
Where PBM is on the firmest ground: wound healing (Tier 1–2), musculoskeletal pain (Tier 2), skin health and acne (Tier 2), athletic recovery (Tier 2).
Where evidence is real but still developing: brain and cognitive support via transcranial/intranasal NIR (Tier 2–3).
What honest evidence review shows: PBM is not effective for every application at every dose. Device parameters matter enormously — studies with under-dosed or improperly configured devices show null results, which is expected given the biphasic dose-response. A well-parameterized device and appropriate protocol produce meaningfully different results than an under-powered one.
Devices We Feature at Resonance Health Hub
Two devices at Resonance Health Hub include photobiomodulation, each targeting a different part of the spectrum for a different primary purpose.
Glowing IC Pad 3
Blue 450nm · Red 630nm · Near-Infrared 850nmThe Glowing IC Pad 3 is primarily an information carrier (IC) delivery platform — it imprints ICs into water or delivers them to the body via PEMF magnetic field. The integrated tri-spectrum LEDs add photobiomodulation as a complementary layer during every IC session.
The blue 450nm component provides surface-level antimicrobial and anti-inflammatory effects at the skin. The red 630nm activates the cytochrome c oxidase pathway in superficial tissue. The NIR 850nm extends PBM effects to deeper tissue layers. All three wavelengths run simultaneously during normal IC delivery use.
This is not a high-power, dedicated PBM device. Its light output is calibrated for IC imprinting and general wellness support. For serious targeted joint applications, a device like the Kineon is more appropriate. For IC delivery with meaningful added PBM benefit, the Glowing IC Pad 3 delivers well on both fronts.
Kineon MOVE+ Pro
Red 660nm LEDs · Near-Infrared 808nm Class 1 LasersThe Kineon MOVE+ Pro is a wearable joint photobiomodulation device purpose-built for targeted musculoskeletal recovery. It combines 660nm red LEDs with 808nm Class 1 near-infrared lasers in a strappable unit designed for knee, shoulder, elbow, and ankle applications.
The 660nm LEDs deliver surface and superficial tissue anti-inflammatory effects and cytochrome c oxidase activation. The 808nm Class 1 lasers provide precisely focused NIR energy delivery at joint depth — enabling the kind of focal dosing that broad LED panels cannot replicate. Class 1 laser classification means the device is eye-safe at normal distances of use.
This is the dedicated PBM tool we recommend when targeted deep-joint photobiomodulation is the primary goal. Its wavelength and power parameters align closely with those used in the positive clinical trials in the musculoskeletal pain literature.
LEDs emit light in a wide cone, diffusing energy across a broader surface area — excellent for general tissue coverage. Lasers emit coherent, collimated light that focuses precisely and penetrates to depth without spreading. In the Kineon, the 808nm Class 1 lasers deliver concentrated NIR energy directly into the joint space — something broader LED panels cannot replicate with the same focal precision. For deep joint applications, this distinction matters.
Why Dosing Parameters Matter
One reason PBM research shows variable results across studies is that dosing parameters vary widely between trials. The Arndt-Schulz law applies here: too little light has no measurable effect, the right dose stimulates, and too much light can actually inhibit. This biphasic dose-response is well-established in the PBM literature and explains why under-powered consumer devices — or clinical devices used with incorrect protocols — often produce null results despite a solid mechanistic rationale.
Key parameters that determine outcome:
- Wavelength — determines depth of penetration and photoreceptor target
- Power density (irradiance) — milliwatts per cm² delivered to target tissue
- Energy density (fluence) — joules per cm² of total energy delivered
- Session duration — must be appropriate for target tissue depth and irradiance
- Treatment frequency — acute presentations typically benefit from more frequent sessions; chronic conditions from regular maintenance
Consumer devices like the Kineon are calibrated with these parameters in mind for their specific joint applications. If you are using the Glowing IC Pad 3 primarily for IC delivery, the PBM dosing is secondary — but the light is real, active, and delivering measured output during every session.
Contraindications
Photobiomodulation has a strong safety profile when applied correctly. The following contraindications apply across all wavelengths and PBM devices:
- Active cancer or suspected malignancy — do not apply PBM directly over tumor tissue
- Direct eye exposure — never direct any PBM device toward the eyes, regardless of wavelength or power level
- Photosensitizing medications — tetracyclines, certain NSAIDs, St. John’s Wort, and others increase photosensitivity
- Directly over the thyroid gland — avoid direct application to this area
- Over the pregnant abdomen — avoid direct application
- Over active hemorrhage or recent hematoma
- Over implanted electronic devices (pacemakers, neurostimulators) — check device-specific guidance
This list is not exhaustive. Always consult a qualified healthcare provider before beginning photobiomodulation, especially if you are taking medications or have an active health condition. For device-specific contraindications, see the Kineon device page and Infopathy device page.
References
All citations link directly to their source. For the complete annotated evidence library, see the Research & Evidence Library.
Wound Healing and Tissue Repair
- Avendaño-Coy J, et al. Electrical microcurrent stimulation therapy for wound healing: a meta-analysis of RCTs. J Tissue Viability. 2022;31(1):63–69. PubMed
Musculoskeletal Pain
- Huang Z, et al. Effectiveness of low-level laser therapy in patients with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015;23(9):1437–1444. PubMed
- de Paula Gomes CAF, et al. Photobiomodulation therapy for osteoarthritis: a systematic review. Photobiomodul Photomed Laser Surg. 2024;42(3):165–178. PubMed
Athletic Recovery
- Leal Junior EC, et al. Effect of phototherapy (low-level laser therapy and light-emitting diode therapy) on exercise performance and markers of exercise recovery: a systematic review with meta-analysis. Lasers Med Sci. 2015;30(2):925–939. PubMed
Brain Photobiomodulation
- Hamblin MR. Shining light on the head: photobiomodulation for brain disorders. BBA Clin. 2016;6:113–124. PubMed
Blue Light — Antimicrobial and Skin
- Cios A, et al. Effects of Blue Light Irradiation on Human Keratinocytes in Vitro. Int J Mol Sci. 2021;22(8):4301. PubMed
Red Light — Skin and Collagen
- Wunsch A, Matuschka K. A controlled trial to determine the efficacy of red and near-infrared light treatment in patient satisfaction, reduction of fine lines, wrinkles, skin roughness, and intradermal collagen density increase. Photomed Laser Surg. 2014;32(2):93–100. PubMed
Near-Infrared — 808nm Clinical Applications
- Tunér J, Hode L. The new laser therapy handbook. Prima Books; 2010. (Comprehensive review of 808nm clinical trials across wound healing, neural regeneration, and pain applications.)
Foundational Mechanism
- Chung H, et al. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516–533. PubMed
- Hamblin MR, Demidova TN. Mechanisms of low level light therapy. Proc SPIE. 2006;6140:614001. DOI
- Karu TI. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. J Photochem Photobiol B. 1999;49(1):1–17. PubMed